Oppenheimer Starts Humacyte (HUMA) at Outperform
- Cyclicals drag S&P 500 lower; Microsoft, Alphabet keep Nasdaq flat
- Ford (F) Stock Up 4% Following Q3 EPS Beat, Reinstated Dividend
- eBay (EBAY) Stock Drops 5% Despite Q3 Beat as Guidance Muted
- Oil drops more than 1% as U.S. stockpiles rise sharply
- Mimecast Limited (MIME) exploring a possible sale - WSJ
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Oppenheimer analyst Suraj Kalia initiates coverage on Humacyte (NASDAQ: HUMA) with an Outperform rating and a price target of $16.00.
The analyst commented, "We are initiating coverage of Humacyte, a recent SPAC merger, with an Outperform rating/$16 PT. An early-stage play in bioengineered vascular grafts, Humacyte has pioneered a human acellular vessel (HAV) for use in vascular grafting. Early results in various Ph2 and POC studies are showing encouraging results in graft patency, ease of use, AE profile, and durability vs. current standard of care—autologous/ePTFE grafts. Fresenius Medical, a key investor in Humacyte, has signed an OUS distribution agreement for HAV. We view Humacyte in two discrete facets—the immediate commercial opportunity in AV access for dialysis and vascular trauma; and the call option in T1 diabetes, which could be paradigm changing. We advise this name only to high-risk tolerance long-duration investors."
Shares of Humacyte closed at $13.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roivant Sciences (ROIV) Stock Surges 20% as Three Street Firms Initiate Coverage With Positive Ratings
- UPDATE: Goldman Sachs Starts Bally's Corp (BALY) at Neutral
- Norfolk Southern (NSC) PT Raised to $301 at Cowen
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesDefinitive Agreement, SPAC
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!